about
Clinical relevance of pharmacological and physiological data in intrathecal baclofen therapy.Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease.Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.Tolerance to continuous intrathecal baclofen infusion can be reversed by pulsatile bolus infusion.Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smokingDisease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulationProtocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-studyA pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity.Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease.FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder.Parkinson's disease, visual hallucinations and apomorphine: A review of the available evidence.Unmet needs in Parkinson's disease: New horizons in a changing landscape.Understanding the role of the Parkinson's disease nurse specialist in the delivery of apomorphine therpy.The role and structure of the multidisciplinary team in the management of advanced Parkinson's disease with a focus on the use of levodopa-carbidopa intestinal gel.How typical are 'typical' tremor characteristics? Sensitivity and specificity of five tremor phenomena.Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients.Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease.Functional (psychogenic) movement disorders associated with normal scores in psychological questionnaires: A case control study.Parkinson bradykinesia correlates with EEG background frequency and perceptual forward projection.Occupational exposure to solvents, metals and welding fumes and risk of Parkinson's disease.Rectal apomorphine: a new treatment modality in Parkinson's disease.Adaptive DBS in a Parkinson's patient with chronically implanted DBS: A proof of principleLateral and Medial Ventral Occipitotemporal Regions Interact During the Recognition of Images Revealed from Noise.Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion.[The possible value of diagnosing MCI-DLB and treatment options]The effects of apomorphine on visual perception in patients with Parkinson disease and visual hallucinations: a pilot study.Variability factors in the expression of stress-induced behavioural sensitisation.The added value of semimicroelectrode recording in deep brain stimulation of the subthalamic nucleus for Parkinson disease.Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.Quick titration of pergolide in cotreatment with domperidone is safe and effective.Occupational exposure to pesticides and endotoxin and Parkinson disease in the Netherlands.Extremely low-frequency magnetic field exposure, electrical shocks and risk of Parkinson's disease.Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.Managing Parkinson's disease with continuous dopaminergic stimulation.Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations.Effect of Pharmacist-Led Interventions on (Non)Motor Symptoms, Medication-Related Problems, and Quality of Life in Parkinson Disease Patients: A Pilot Study.Substituting the Target After Unsatisfactory Outcome of Deep Brain Stimulation in Advanced Parkinson's Disease: Cases From the NSTAPS Trial and Systematic Review of the Literature.
P50
Q30828677-3BF762C5-71B7-4FDC-B9D0-E2795FA7C76EQ32132635-54760F42-72FA-4EC5-962E-88F710AF6123Q33747108-13263DD7-20F0-4C30-BAB4-BD5BE8329052Q34032505-3DFA6249-C2B2-4DCA-8408-7F473018C658Q35013253-637A3AAC-38A9-4213-84AB-382DC7FF827EQ35129374-48925B5A-5211-473D-BB99-A76C4ABCDE3DQ35161661-09DC6EE3-6573-4C27-851F-5F17516F22E2Q35490116-D6D23A61-45D2-400F-9E86-C21C12016C44Q35846382-10B8F72C-185A-446B-8951-00F1272939AEQ36410225-10AC7324-F8EB-4062-AACB-6B5A88112874Q37725119-06DAA816-66D4-44E2-B068-19627985AF62Q38666938-731042F2-63F8-4ADE-90BE-B5B57466B8B9Q38821958-3FF51394-367E-4B1D-AD41-F6AEA80F4371Q39033580-E1836AE8-DBCC-4455-B514-4029E085B97BQ39034936-C029567E-8A60-4190-82EC-88226C203E9AQ39099746-57B09FA3-67CB-41E0-9E6A-6D0043C75EC3Q39653413-D35ADEC0-EEDF-4D75-A6E5-52D69BCEB337Q40166426-C3F4A973-41BF-4AE4-9BBE-E0C60AF90453Q40694060-8205A40F-FB13-4136-A29F-3A92B88241F9Q40794985-BB9EDFEF-CF2B-4470-81B1-D25183250060Q40926597-334AA3A9-3AE8-4E32-AC3F-A910F2D463B4Q41028139-83265045-F46E-4361-9F16-A4D1B98EE046Q41381176-2B55F5AE-2530-4FF4-8009-5C01A2F308CDQ41591306-9ED03DB8-0C0F-4F12-913A-7F6322B4530CQ41873930-277490FA-190C-4A84-B5C3-31DCBEFE2C7DQ42545277-F469BD3A-610D-4585-8833-BB66E569D44DQ43188886-61D02594-84D6-4A66-B929-15B72E7CA640Q43294938-A2B34592-9E80-42E9-B467-BA4A64E6B355Q43351594-7B1910E0-8C48-4354-86BA-2732C6964A2AQ43430003-D05933C3-6CF0-4F41-8282-CB5B90B49E99Q43570440-26E7517D-80B4-4C61-A3B0-9C4FC9B25799Q43629215-845A0C4D-8AB6-43F6-AB5D-BF31D9113E34Q43867195-55B96D20-C7F1-4259-A203-79ED75F6A368Q45046252-2CCEF0CF-5AC0-4D4E-9A6D-2FB824A1DDE9Q45970216-E541BBC1-0CEB-4024-9D18-2E96B958C7FDQ46517959-B674C53B-1E2C-44CA-99E3-FC9791D317FEQ46647668-C63E3621-CD5D-4855-8138-D6C50F5FADFCQ46713971-7A2278A4-53C9-4A6B-AD05-C45160D46598Q47210848-AD93E4F1-109C-4846-9797-0F001EC3752BQ47430209-0F035E03-0BEB-484C-8D73-36FBDD7739BB
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0001-5088-480X
@en
name
Teus van Laar
@ast
Teus van Laar
@en
Teus van Laar
@es
Teus van Laar
@nl
type
label
Teus van Laar
@ast
Teus van Laar
@en
Teus van Laar
@es
Teus van Laar
@nl
altLabel
van Laar T
@en
prefLabel
Teus van Laar
@ast
Teus van Laar
@en
Teus van Laar
@es
Teus van Laar
@nl
P106
P1153
7003630275
P31
P4012
P496
0000-0001-5088-480X